Live Breaking News & Updates on Biomedica Plc|Page 3

Stay updated with breaking news from Biomedica plc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

- Formed New AAV Manufacturing and Innovation Business with Oxford Biomedica to Leverage Homology’s Process Development and Manufacturing Capabilities - - Received $130 Million Non-Dilutive. | March 23, 2022 ....

Tim Kelly , Cara Mayfield , Theresa Mcneely , Oxford Biomedica , Arthur Tzianabos , Albert Seymour , Company Contacts , Company Updates Guidance , Drug Administration , Corporate Communications , European Medicines Agency , Homology Medicines Inc , Program Updates , Globenewswire Inc , Innovation Business , Leverage Homology , Manufacturing Capabilities , Non Dilutive Capital , Significantly Extends Cash Runway , Editing Trial , Gene Therapy Trial , Hunter Syndrome , Program Updates Expected , Therapy Trial , Chief Executive Officer , Chief Scientific Officer ,

Oxford BioMedica plc: Oxford Biomedica broadens its viral vector capabilities with the launch of Oxford Biomedica Solutions, a full scope AAV business in Boston, following closing of its deal with Homology

Unique platform offering capabilities from vector design and process development through to clinical trials is now available to new customers Oxford, UK - 11 March 2022: Oxford Biomedica plc (LSE:OXB) ....

United Kingdom , Tim Kelly , Mary Jane Elliott Matthew Neal , Stuart Paynter , Oxford Biomedica , Sophia Bolhassan , Homology Medicines Inc , Consilium Strategic Communications , Oxford Biomedica Solutions , Homology Medicines , Adeno Associated Virus , Drug Substance , Drug Product , United Kingdom Based , Chief Financial , Strategic Communications , Jane Elliott ,

DGAP-News: 'Game Changing' Technology Enables QR Code Integration with 3D Screen Printing

DGAP-News: Laxxon Medical / Key word(s): Miscellaneous Game Changing Technology Enables QR Code Integration with 3D Screen Printing 16.02.2022 / 11:50 The issuer is solely responsible for the content of this announcement. NEW YORK, NY / ACCESSWIRE / February 16, 2022 / A study in the Biomedica. ....

New York , United States , Achim Schneeberger , Frances Hoggard , Game Changing Technology Enables Qr Code Integration , Laxxon Medical Corporation , Biomedical Journal Of Scientific Technical Research , Distribution Services , Laxxon Medical Corp , Technology Screen Printing Innovational Drug , News Service , Laxxon Medical , Game Changing Technology Enables , Screen Printing , Biomedical Journal , Technical Research , Quick Response , Screen Printed Tablet , Screen Printing Innovational Drug Technology , Public Relations , Corporate News , Regulatory Announcements ,

Oxford Biomedica Says Sio Gene Intends To End AXO-Lenti-PD License Deal

LONDON (dpa-AFX) - British gene and cell therapy company Oxford Biomedica Plc (OXB), said that Sio Gene Therapies has informed that it intends to return the global rights for AXO-Lenti-PD, a gene ....

United Kingdom , City Of , Oxford Biomedica , Pavan Cheruvu , Oxford Biomedica Plc , Sio Gene Therapies , United Kingdom Based ,

Oxford BioMedica plc: Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines' established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with Homology Medicines as 20% owner

Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines' established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business ....

United States , United Kingdom , Mary Jane Elliott , Ukand Bedford , Stuart Paynter , Matthew Neal , Cara Mayfield , Theresa Mcneely , Arthur Tzianabos , Oxford Biomedicabroadens , Oxford Biomedicaand John Dawson , Roch Doliveux , Oxford Biomedicaanalyst , John Dawson , Oxford Biomedicafor , Oxford Biomedica , Sophia Bolhassan , Listing Rules Of The Financial Conduct Authority , Financial Services , Group Board , Oxford Biomedica Solutions , Exchange Commission , European Union Withdrawal , Corporate Communications , Homology Medicines Inc , Consilium Strategic Communications ,